STAT+: Abridge CTO talks Epic, Microsoft, and rebranding as ‘more than an AI scribe’
Stat News • 2/10/2026
Summary
Abridge CTO Zach Lipton discusses the evolving market for AI scribes. He addresses topics related to Epic and Microsoft, and the company's rebranding as "more than an AI scribe."
Advertisement
Lindy Score Breakdown (V4.2)
53d
Age
1
Sources
from cluster
1268
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1268/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1268/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 52 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Large AI scribe study finds modest time savings, inconsistent use
Stat News • 2 days ago
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • 1 day ago
STAT+: NIH director’s invocation of Vannevar Bush’s legacy to promote Trump science policies sparks pushback
Stat News • 2 days ago
STAT+: Trump administration prepares 100% tariffs on some imported drugs
Stat News • 2 days ago
STAT+: NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along
Stat News • Today
STAT+: White House proposes 12% cut to federal health agencies in 2027 budget request
Stat News • Today
STAT+: Biotech investors’ plea to Trump, and a busy M&A week
Stat News • Today
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
Stat News • 1 day ago
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 1 day ago
STAT+: The biotech scorecard for the second quarter: 23 stock-moving events to watch
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago